Semaglutide Program from Peak Medical Its being touted as a game-changer in the world of weight loss drugs because, well, it actually works
In light of these mixed findings, there is a need for further RCTs specifically assessing these outcomes with adequate follow up as these events may not occur soon after the start of therapy
Clinical trials for GLP-1 agonists have found that nausea occurs in 15% to 30% of patients, diarrhea in 10-15%, and vomiting in 5-10% (usually as a result of the nausea)
Treatment plans are customized based on individual goals, medical history, and response to the medication
On one hand, it can adhere to the intestinal mucosa to control the permeability of other bacteria, nutrients, and cellular metabolites
There is no evidence that semaglutide increases the risk of food poisoning